Peptide Tools to Study Human Papillomavirus (HPV)

About Human papillomavirus

Human papillomavirus (HPV) belongs to the papillomavirus family and infects keratinocytes of the skin or mucous membranes. HPV is the most common sexually transmitted infection globally. While many of the more than 170 known types of HPV cause no symptoms, some types can cause warts (HPV6 and HPV11), while others can lead to cancer (HPV16, HPV18, HPV31, HPV45).

HPV & Cancer
Some HPV types lead to cancer of the cervix, vulva, vagina, anus, penis and mouth or throat. Almost all cases of cervical cancer are due to HPV (mostly HPV16 and HPV18). Other high risk HPV types are HPV31 and HPV45.
Some of the early genes, such as E6 and E7, act as oncogenes that promote tumor growth and malignant transformation. For example, E6 protein inactivates the tumor-suppressor protein p53 leading to unregulated cell division and cell growth. Furthermore, HPV can integrate into the host genome which is associated with alterations of genes and gene regulation.

HPV Vaccines & Diagnosis
HPV vaccination prevents the most common types of infection and is recommended for preteen males and females aged 9-13. With cervical cancer screening (pap test), cancer precursor cells can be detected early on.

JPT's Peptide Tools to Study HPV

Cellular Immune Response

-> PepMix™ Peptide Pools 
  • Antigen specific stimulation of T-cells
  • Immune monitoring of high-risk patients
  • Qualification of immunodominant antigens
  • Validating clinical T-cell assays
PepMixes™ HPV
We offer 21 different antigen-spanning HPV PepMixes from e.g. HPV06, HPV11, HPV16, HPV18, HPV35, HPV45 and HPV58 covering proteins such as E1, E2, E4, E5, E6, E7 and L1.

Tailored PepMix™ Peptide Pools for your specific needs!

  • T-cell assays in
  • High-throughput T-cell epitope discovery
  • Monitoring of cellular immune response
  • Clinical trials

We are the experts for peptide synthesis with highest quality optimized for many applications. Our peptide synthesis service has a very high success rate (over 99%) as we optimize the appropriate peptide synthesis method for each peptide.
If you would like to order a quality peptide synthesis using regulated processes, choose JPT!

Humoral Immune Response

-> Peptide Microarrays 
  • Immune monitoring of humoral responses
  • Profiling of HIV specific samples or antibodies
  • Evaluation of co-infection
  • Detection of epitopes and epitope spreading

Tailored PepStar™ Peptide Microarrays
You define content and layout, we provide economic and fast production in our regulated clean-room environment. We also offer our assay and analysis service using your samples with your tailored peptide microarray.

Our tailored Peptide ELISA plates are offered as stand alone service for mapping of epitopes and definition of protein interaction sites or as validation assay to confirm results obtained with JPT’s peptide microarrays.

Clinical Peptides

-> Clinical Peptides
JPT’s Clinical Peptides product lines Clinical Grade and ISO Plus are produced in production environments that are regulated by an enhanced ISO 9001:2015 quality management system for the stringent product requirements of immunotherapy as well as vaccine and drug development. Depending on the specifics of the immunotherapy concept to be applied, the resulting products have been shown to be applicable in clinical applications.



  • Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies
    Minnar et al., Journal of Immunology (2022) - PMID: 35764364
    Product used: PepMix HPV 16 (E7)
  • Incorporation of RG1 Epitope Into HPV16L1-VLP Does Not Compromise L1-Specific Immunity
    Schellenbacher et al, Vaccine (2019)
  • Characterization of Recombinant Gorilla Adenovirus HPV Therapeutic Vaccine PRGN-2009
    Samuel T. Pellom et al., JCI Insight, (2021)
  • First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers
    Fenne L. Komdeur et al., Mol Therapy, (2021)
  • Human Papilloma Virus-Specific T Cells can be Generated from Naïve T Cells for use as an Immunotherapeutic Strategy for Immunocompromised Patients
    McCormack et al., Cytotherapy (2018)
  • Development of a Replication-Deficient Adenoviral Vector-Based Vaccine Candidate for the Interception of HPV16- and HPV18-Induced Infections and Disease
    Ramos et al., International Jounal of Cancer (2017)
  • Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV)
    Huber et al., PLoS One (2017)



“The RV 144 HIV trial is considered as one of the first successful HIV vaccine trials. It has become clear that the V2 loop of gp120 is an important site for immunogenicity and protection from HIV infection. The use of JPT’s PepStar™ microarray technology has been very useful for the correlation of the clincial outcome with humoral immune responses. As have the cyclic peptides been from JPT to validate these findings!”
J. Currier, PhD., Walter Reed Army Institute, Rockville, Maryland, USA


Check our list of products, click and go.

Get a quote